|
Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, announces the fund's first exit since launching in 2016. In 2017, the Helsinn Investment Fund was co-leader in the Series B financing round in Swiss biotech, AMAL Therapeutics, which raised €8 million (CHF 8.8 million). The continued investment in AMAL since then has enabled the company's continued growth and development in the field of peptide-based therapeutic cancer vaccines.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "The Helsinn Investment Fund congratulates AMAL for this tremendous achievement enabling accelerated development toward improving outcomes for cancer patients worldwide. Although we delivered toward our...
|